Feedback (LSE:FDBK), the AIM-quoted clinical software company behind the Bleepa platform, remains in a holding pattern as it waits for a potential national contract decision from NHS England. Its most recent trading update, published on 14 July 2026, showed tight cost control and a cash runway extending to mid-2027, but the timing of the decision that could reshape the Business sits outside the company's control.
What the Company Does
Feedback describes itself as a clinical infrastructure specialist. Its main product, Bleepa, is a clinical communication and digital pathway platform used by NHS organisations to share images and records, manage referrals and move patients through community-based diagnostic and care pathways. The aim is to reduce unnecessary outpatient appointments and speed up decision-making by clinicians.
Latest Developments
On 20 April 2026, Feedback told investors that a decision on a potential contract for a widescale Bleepa programme, previously expected around the end of March, would be delayed by at least six to nine months because of factors internal to the NHS. At the same time, NHS England extended Bleepa licences at Queen Victoria Hospital to cover the nine months ending December 2026, at an annualised contract value of £495,000. A further annual extension was agreed with Northern Care Alliance NHS Foundation Trust, while a photocapture contract with Royal Berkshire NHS Foundation Trust was not renewed after its three-year term ended.
In the July trading update, the company said it hoped for a national contract decision around the end of the calendar year, subject to NHS England and HM Treasury completing their evaluation. It also reported completed integrations with the NHS e-Referral Service, Patients Know Best and the Evolve electronic medical record, plus the release of Bleepa version 1.7. Following the e-Referral integration, the number of GP practices referring into Bleepa rose tenfold within a few weeks, and the company said all breathlessness patients in Sussex had been diverted away from outpatient appointments over a recent three-month period.
Financial Picture
For the year ended 31 May 2026, unaudited Revenue was about £0.8 million, compared with £0.9 million a year earlier. The company said its EBITDA loss was smaller than both management expectations and the previous year, helped by cost controls, and year-end cash of £2.7 million was ahead of expectations thanks to faster collections. Feedback does not pay a dividend. No audited final results for the year were found at the time of writing.
Sector and index Context
Feedback is among the smallest constituents of the FTSE AIM All Share Index. Market data, updated on 7 October 2026, showed a share price of around 6.3p and a Market Capitalisation of about £3 million. Digital health suppliers to the NHS often face long procurement cycles and funding decisions that can shift with central budgets, and the company has said it expects new frontline digitisation funding during the 2026/27 NHS financial year.
Key Risks
The central risk is concentration on a single potential national contract whose timing has already slipped. Revenue remains small, and the cash runway to mid-2027 leaves limited room if decisions are delayed further, raising the possibility of future fundraising. Contract non-renewals, such as the Royal Berkshire photocapture contract, also show that existing revenue streams are not guaranteed.
What to Watch Next
Investors will be watching for any NHS England and HM Treasury decision on the Bleepa programme, the outcome of the Queen Victoria Hospital arrangement beyond December 2026, the rollout of new clinical pathways and the publication of audited results for the year to May 2026. Chief executive commentary in July described the company as approaching a pivotal moment.
_11_18_2026_09_42_19_750506.jpg)
_11_18_2026_09_43_10_583784.jpg)




Please wait processing your request...